The clinical progression of patients with glioblastoma
Background: Glioblastoma is the most aggressive and common primary brain tumor. Patients usually present with a short clinical history that often includes focal neurological deficits. Historically 1- and 5-year survival of patients with this disease has been low. There are now increasing reports of...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-06-01
|
| Series: | Interdisciplinary Neurosurgery |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214751923000397 |
| _version_ | 1797867385720406016 |
|---|---|
| author | Allison L. Hansen Shashvat M. Desai Angelina N. Cooper Mackenzie A. Steinbach Kevin Gosselin John E. Wanebo |
| author_facet | Allison L. Hansen Shashvat M. Desai Angelina N. Cooper Mackenzie A. Steinbach Kevin Gosselin John E. Wanebo |
| author_sort | Allison L. Hansen |
| collection | DOAJ |
| description | Background: Glioblastoma is the most aggressive and common primary brain tumor. Patients usually present with a short clinical history that often includes focal neurological deficits. Historically 1- and 5-year survival of patients with this disease has been low. There are now increasing reports of patients living longer, making it important to understand the clinical progression of the disease to predict patient needs. Methods: Patients ≥ 18 years who were enrolled in the central nervous system (CNS) tumor registry at HonorHealth in Scottsdale, Arizona between April 7, 2017 and February 5, 2020 were included. Demographic data and data on adverse events were collected from the CNS tumor registry. The data was analyzed and reported as means and standard deviations. Results: 12 male and 7 female patients were included in the study. The average time to follow-up was 15.12 months and patients experienced the onset of psychiatric/neurological adverse events an average of 3.29 months after surgery, cardiovascular/respiratory adverse events 3.42 months after surgery, and general adverse events 3.71 months after surgery. Additionally, 63.2% of patients experienced a seizure with an average time to onset of 6.75 months after surgery. Conclusions: Patients with glioblastoma experience psychiatric/neurological adverse events first, followed by cardiovascular/respiratory adverse events, and finally followed by general adverse events. Most patients will experience at least one seizure. |
| first_indexed | 2024-04-09T23:39:25Z |
| format | Article |
| id | doaj.art-62e87e27931542409bb89a74c305a8b3 |
| institution | Directory Open Access Journal |
| issn | 2214-7519 |
| language | English |
| last_indexed | 2024-04-09T23:39:25Z |
| publishDate | 2023-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Interdisciplinary Neurosurgery |
| spelling | doaj.art-62e87e27931542409bb89a74c305a8b32023-03-19T04:37:59ZengElsevierInterdisciplinary Neurosurgery2214-75192023-06-0132101756The clinical progression of patients with glioblastomaAllison L. Hansen0Shashvat M. Desai1Angelina N. Cooper2Mackenzie A. Steinbach3Kevin Gosselin4John E. Wanebo5The University of Arizona College of Medicine – Phoenix, 475 N 5th St., Phoenix, AZ 85004, USAHonorHealth Research and Innovation Institute, 10510 N 92nd St Suite 200, Scottsdale, AZ 85258, USAHonorHealth Arizona Spine Group, 7242 E Osborn Rd Suite 230, Scottsdale, AZ 85251, USAHonorHealth Arizona Spine Group, 7242 E Osborn Rd Suite 230, Scottsdale, AZ 85251, USAHonorHealth Arizona Spine Group, 7242 E Osborn Rd Suite 230, Scottsdale, AZ 85251, USADepartment of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center. 350 W Thomas Rd, Phoenix, AZ 85013, USA; Corresponding author at: Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, 350 W Thomas Rd, Phoenix, Arizona 85013, USA.Background: Glioblastoma is the most aggressive and common primary brain tumor. Patients usually present with a short clinical history that often includes focal neurological deficits. Historically 1- and 5-year survival of patients with this disease has been low. There are now increasing reports of patients living longer, making it important to understand the clinical progression of the disease to predict patient needs. Methods: Patients ≥ 18 years who were enrolled in the central nervous system (CNS) tumor registry at HonorHealth in Scottsdale, Arizona between April 7, 2017 and February 5, 2020 were included. Demographic data and data on adverse events were collected from the CNS tumor registry. The data was analyzed and reported as means and standard deviations. Results: 12 male and 7 female patients were included in the study. The average time to follow-up was 15.12 months and patients experienced the onset of psychiatric/neurological adverse events an average of 3.29 months after surgery, cardiovascular/respiratory adverse events 3.42 months after surgery, and general adverse events 3.71 months after surgery. Additionally, 63.2% of patients experienced a seizure with an average time to onset of 6.75 months after surgery. Conclusions: Patients with glioblastoma experience psychiatric/neurological adverse events first, followed by cardiovascular/respiratory adverse events, and finally followed by general adverse events. Most patients will experience at least one seizure.http://www.sciencedirect.com/science/article/pii/S2214751923000397Adverse eventsBrain tumorClinical progressionGlioblastomaSurvival |
| spellingShingle | Allison L. Hansen Shashvat M. Desai Angelina N. Cooper Mackenzie A. Steinbach Kevin Gosselin John E. Wanebo The clinical progression of patients with glioblastoma Interdisciplinary Neurosurgery Adverse events Brain tumor Clinical progression Glioblastoma Survival |
| title | The clinical progression of patients with glioblastoma |
| title_full | The clinical progression of patients with glioblastoma |
| title_fullStr | The clinical progression of patients with glioblastoma |
| title_full_unstemmed | The clinical progression of patients with glioblastoma |
| title_short | The clinical progression of patients with glioblastoma |
| title_sort | clinical progression of patients with glioblastoma |
| topic | Adverse events Brain tumor Clinical progression Glioblastoma Survival |
| url | http://www.sciencedirect.com/science/article/pii/S2214751923000397 |
| work_keys_str_mv | AT allisonlhansen theclinicalprogressionofpatientswithglioblastoma AT shashvatmdesai theclinicalprogressionofpatientswithglioblastoma AT angelinancooper theclinicalprogressionofpatientswithglioblastoma AT mackenzieasteinbach theclinicalprogressionofpatientswithglioblastoma AT kevingosselin theclinicalprogressionofpatientswithglioblastoma AT johnewanebo theclinicalprogressionofpatientswithglioblastoma AT allisonlhansen clinicalprogressionofpatientswithglioblastoma AT shashvatmdesai clinicalprogressionofpatientswithglioblastoma AT angelinancooper clinicalprogressionofpatientswithglioblastoma AT mackenzieasteinbach clinicalprogressionofpatientswithglioblastoma AT kevingosselin clinicalprogressionofpatientswithglioblastoma AT johnewanebo clinicalprogressionofpatientswithglioblastoma |